A two dimensional coupled model of drug delivery in the cardiovascular tissue using biodegradable drug eluting stents is developed. Qualitative behavior, stability analysis as well as simulations of the model have been presented. Numerical results computed with an implicit explicit finite element method show a complete agreement with the expected physical behaviour.
Introduction
A stent is a metallic scaffold that is inserted in a restricted part of a narrowed blood vessel. A drug eluting stent (DES) consists of a stent coated with a polymeric layer that encapsulates a therapeutic drug to reduce smooth muscle cell growth and to prevent an inflammatory response.
These are the predominant causes of neointimal proliferation and in-stent restenosis that is the re-narrowing of blood vessels after stent implantation. Application of DES for prevention of restenosis is a promising technology which combines the mechanical support of the vessel with local drug delivery.
Drug release depends on many factors, such as the geometry and location of the vessel, the geometry of the stent, the coating properties as its chemical composition and porosity, and drug characteristics as for example its diffusivity. Due to the involvement of so many factors, prediction of drug release represents an important issue and mathematical models are a useful tool to design an appropriate drug delivery system [3, 11] . The use of mathematical models and numerical simulation can give further insight on the pharmacokinetics of cardiovascular drug During the last years, a number of studies have proposed mathematical models to describe drug delivery in the cardiovascular tissues. We refer without being exhaustive [3 − 10, 13] and also [11] as a review paper. Most of these studies address the release of drug and its numerical behavior in one dimension, while the behaviour of the biodegradable materials is disregarded.
Pontrelli and de Monte [7 − 9] developed a mathematical model for drug release through a drug eluting stent in contact with the vessel wall as a coupled cardiovascular drug delivery system. They analyzed numerically and analytically the drug release from the coating into both an homogeneous mono-layer wall [7] and an heterogenous multi-layered wall [9] in one dimension. Despite their interesting results, the biodegradation process of the carrier polymer, the penetration of the biological fluid into the coating and the egression of materials from the coating have not been taken into account.
Prabhu and Hossainy [10] developed a mathematical model to predict the transport of drug with simultaneous degradation of the biodegradable polymer in the aqueous media. These authors use a simplified wall-free condition, in which the influence of the arterial wall is modeled through the coupling with a Robin boundary condition. An important feature of this model, which differentiates it from other models, are the conditions used to represent the polymer degradation.
It is assumed that a set of oligomers can be identified as one compartment, characterized by a certain molecular weight range, whose their diffusion characteristics and degradation kinetics can be considered to be identical. Furthermore, the model in [10] takes into account the underlying chemical reactions responsible for degradation in a more detailed form than the models presented by other researchers. It also accounts for the increase of diffusivity of the different species involved as time evolves. In this paper, while following the approach in [10] , we have completed the model with the dynamics of the drug in the arterial vessel.
The geometrical and mechanical effects of the metalic part of the stent in degradation and drug release as well as the penetration of the oligomer and lactic acid into the vessel wall are considered 2 negligible. As the transport properties through the glycocalyx (the coverage of endothelium) are unknown, we have considered the values of the parameters in the endothelium layer. A perfect sink condition at the interface between the vascular wall and the vascular lumen are considered.
The paper is organized as follows. Section 2 is devoted to the description of the model and its initial, boundary and interface conditions. In Section 3 we briefly explain the mass behaviour of the materials. In Section 4 we present a variational formulation and we establish a stability result for the continuous model and in Section 5, using an implicit explicit finite element method, we establish a discrete variational form of the problem. Numerical simulations are discussed in Section 6.
Description of the model
We consider a stent S coated with polylactic acid (PLA) containing the drug and in contact with the vessel wall V (Figure 2 ). In the stent S, Γ 1 is the boundary between the coated stent and the metalic part of the stent that is stent structure while Γ 2 and Γ 3 are the boundaries which separate the coated stent and the lumen. Γ 4 is an interface boundary which separates the coated stent from the arterial wall. In the vessel wall V , Γ 5 and Γ 6 are the boundaries between the vessel wall and the lumen while Γ 7 is the boundary between the vessel wall and the tissue (outer part of the vessel wall). Finally Γ 8 and Γ 9 are virtual boundaries where symmetry conditions are imposed to simplify the model. 
where C 1,S , C 2,S , C 3,S and C 4,S represent the concentrations of the fluid, PLA, oligomers and lactic acid in the coating respectively, that are defined in (x, y, t) ∈S × IR + . The constants κ 1,S and κ 2,S stand for the reaction rates of the first and second reactions respectively.
In the coating, the problem is described by the following nonlinear reaction diffusion equations
where C 5,S denotes the concentration of the drug in the coating, and the reaction terms are defined by
In (3), F 1 and F 2 are defined by
where α and β are positive dimensional constants (see the Annex for more details).
The diffusivities of the fluid, oligomers, lactic acid and drug will evolve with time. This variation occurs due to the progressive degradation of the polymer as well as to the swelling of the polymer.
The diffusivities D m,S of the species in the stent coating, will attain a lower bound in the PLA and an upper bound in the fluid. It is therefore assumed that the diffusion coefficients increase exponentially with the extent of the hydrolysis of PLA. We represent these diffusivity coefficients in the coated stent by
where D 0 m,S is the diffusivity of the specie m in the unhydrolyzed PLA and C 0 2,S is the unhydrolyzed polymer concentration at the initial time.
For the vessel wall, a diffusion equation with constant diffusion coefficient D V is considered
where C V stands for the drug concentration in the vessel wall. Although the concentrations depend on time and space, we will consider often explicitly the time variable, omitting the space variable. Since the degradation starts at t = 0, we assume there is no initial concentration of oligomers and lactic acid in the coating and that the drug and PLA are uniformly distributed.
In the coated stent and the vessel wall, the initial conditions are defined by
We also assume that the boundary Γ 1 , interface between the coating and the stent structure, is impermeable to the materials which means that no mass flux crosses it, that is
where η S is the exterior unit normal to Γ 1 .
We assume that the blood flow in the arterial lumen does not significantly influence the drug release and the transport in the arterial wall tissue. In Γ 2 and Γ 3 , the boundary conditions are defined by
where γ m,S , m = 1, . . . , 5, represent partition coefficients.
To couple the transport od drug in the coated stent and the vessel wall, the continuity of the mass flux and the concentration are assumed, that is
where η S = −η V . We also assume that Γ 4 is impermeable to other compounds.
In what concerns the interface layer between intima and media, a Robin condition of type
is considered.
On Γ 8 and Γ 9 , a homogeneous Neumann boundary condition D V ∇C V .η V = 0 is assumed which 5 represents a no flux condition. The flux of drug from the arterial wall to the blood is given by
where γ b is such that the endothelium offers a small resistance to the drug transport.
Summarizing, the boundary and interface conditions of the problem are defined by the following set of equations:
The meaning and units of all variables and parameters used in the model are presented in Table   2 (Annex).
Qualitative behaviour of the total mass of the system
In what follows we analyse the time behaviour of the total mass
where S and V stand for the stent and the vessel wall domains.
As we have
considering (2) and (6), and taking into account the boundary conditions we obtain
where the measures of the boundaries are defined by the length.
The coupling conditions (10) lead to
where
and
We note that ∆M Γ (t) represents the mass of molecules that enters, per unit time, in the lumen; ∆M H (t) stands for the mass of lactic acid produced by unit time, and resulting from the hydrolysis of oligomers. Finally, integrating in time we deduce
This equality means that the total mass in the system at time t is given by the difference between the initial mass added with the mass of fluid that enters in the system until time t and the mass of hydrolyzed oligomers until time t, the mass of the components that are on the boundary until time t: fluid (C 1,S ), PLA (C 2,S ), oligomers and lactic acid (C 3,S , C 4,S ) respectively, and drug, C 5,S , and C V .
Weak formulation of the coupled problems
In this section, we introduce a variational problem induced by the initial boundary value problem (IBVP) (2) − (6) and (13) . We start by introducing some notations.
Let Ω be a bounded domain in IR 2 with boundary ∂Ω. By L 2 (Ω), H 1 (Ω) and L 2 (∂Ω) we denote the usual Sobolev spaces endowed with the usual inner products (., .), (., .) 1 , and (., .) ∂Ω , respectively, and norms . L 2 (Ω) and .
Let T > 0 be fixed. The space of functions v : (0,
Let Ω S,V = S ∪ V ∪ Γ 4 and C, γ, D and C * be defined by
In what follows we consider the weak solution of the initial boundary value problem (IBVP) (2) − (6) and (13) defined by the variational problem:
In what follows we study the behaviour of the solution of the initial value problem VP. Let the 8 energy functional E ∇ (t) be defined by
where E ∇ (0) is the initial mass of PLA and drug. In the following, the space
will be represented by L ∞ (L ∞ ).
such that the following holds
where |Γ 2 ∪ Γ 3 | is the length of the boundary Γ 2 ∪ Γ 3 .
Proof. Taking in (17), v m = C m,S (t) and w = C(t) we obtain
that leads to
As H 2 (S) is embedded in the space of continuous bounded functions in S ([1]), it can be shown that there exists a positive constant
Inequality (21) leads to the differential inequality
and consequently we deduce (19).
In order to simplify the presentation, we assume in what follows that the diffusion coefficients D m,S , m = 1, . . . , 5, are constant. To study the stability of the initial value problem VP, we consider two solutions C = (C * , C) andC = (C * ,C) with different initial conditions C(0) and C(0). To establish an inequality of form
where B(t) must be bounded in time, that leads to the stability a system of quasi-linear reactiondiffusion equations, it is sufficient to assume that the reaction terms have bounded partial derivatives. As reaction terms (3) are nonlinear functions unbounded partial derivative, an estimate of type (23) can not be established. To gain some insight on the stability behaviour of the initial value problem VP, we study in what follows the stability of a linearization of VP in the neighborhood of a soloution C(t).
We recall that C * (t) = C m,S (t) m=1,...,4
, and C(t) and D are defined by (14) and (16) respectively. Then, the system of equations (2) and (6) can be rewritten in the following form
is defined by
and F m,S (C * (t)), m = 1, . . . , 4, are given by (3) and (4).
The linearization of the initial value problem (24) in C(t) is then written in the following form
10 withC(t) = (C * (t),C(t)),C * (t) = C m,S (t) m=1,...,4
In (28), F J,i (C(t))C(t), i = 1, 2, represent Fréchet derivatives defined by
(29)
LetC andC be solutions of the variational problem associated with the initial boundary value problem defined by (26) and the conditions (13), with initial conditionsC(0) andC(0). We suppose thatC(t),C(t) ∈ H 2 (S)
We establish in what follows an upper bound for the functional E W (t) defined by
where W m,S =C m,S −C m,S , m = 1, . . . , 4, and
It can be shown that
Consequently, there exists a positive constant
This inequality leads to
which allow us to conclude the stability of the linearization of VP for bounded time intervals.
Finite dimensional approximation
To define a finite dimensional approximation for the solution of VP we fix h > 0 and we introduce in Ω S,V an admissible triangulation T h , depending on h > 0, such that the corresponding admissible triangulations induced in S and V , respectively T h S and T h V , are compatible on Γ 4 (see Figure 3) . To compute the semi-discrete Ritz-Galerkin aproximation C h = (C * h , C h ) for the weak solution C = (C * , C) defined by VP, we introduce the finite dimensional spaces
where Q = S, Ω S,V and P n denotes a polynomial with degree at most n.
Let C * h = (C 1,S,h , C 2,S,h , C 3,S,h , C 4,S,h ) and
The Ritz-Galerkin approximation C h = (C * h , C h ) for the weak solution C = (C * , C) defined by VP, is computed solving the following variational problem:
, and
Following the proof of Theorem 4.1 it can be shown that E ∇ (t) defined with the Ritz-Galerkin approximation C h = (C * h , C h ) satisfies an inequality analogous to (19). Moreover, for the linearization of FEVP around C h = (C * h , C h ) it can be shown an inequality analogous to (34).
Numerical Experiments
In In Figure 4 , we plot the drug distribution in the stent and in the arterial wall after 1 day, 7
and 14 days. When the drug reaches Γ 4 (See Figure 2) , it crosses the arterial wall through the interface boundary as mathematically described by (10) . When the drug reaches the boundary Γ 7 , it enters the media as described by Robin boundary conditions (11).
14 (a) 1 day.
(b) 7 days.
(c) 14 days. In Figure 5 , we exhibit the penetration of the fluid into the coated stent. We observe that the fluid penetrates into the PLA until it reaches a steady state level. In Figure 6 , the degradation of PLA into smaller molecules which are released into the lumen is shown. It is assumed that the penetration of the PLA and also its reaction products, oligomers and lactic acid, into the arterial wall is negligible. The evolution of PLA concentration is compatible with erosion during degradation. In Figure 7 , we exhibit the mass of drug both in the coating and in the vessel wall as well as the mass of the fluid, PLA and lactic acid in the coating during the first 12 hours using different diffusion coefficients. We observe in Figure 7 (a) that small diffusion coefficients will increase accumulation of the drug in the vessel wall resulting in higher drug residence time and also will increase the mass of fluid and lactic acid in the stent. In Figure 7 (b) , an increase in the PLA degradation and drug release is observed when the diffusion coefficients of the drug and the fluid decrease. We compute the mass fractions retained in the coating by
where |S| represents the area of S. The mass of drug in the vessel is defined by
where |V | stands for the area of the vessel wall. Figure 8 shows the influence of reaction rates on the release process. In Figure 8 (a) we observe that when the reaction rate κ 1,S decreases, more fluid enters the stent. A little increment will also accur when we decrease κ 2,S . As it is seen in Figure 8 (b) , when both the values of the reaction rates κ 1,S and κ 2,S are decreased, some reduction in lactic acid production is observed. Table 1 : Behaviour of the mass of the fluid, PLA, oligomers and lactic acid for different valuse of α and β (s/cm 2 ) after 24 hours. Table 1 shows the effect of the autocatalysis coefficients on the degradation of the polymer. As it can be observed, the polymer degrades slightly faster at higher values of the autocatalysis coefficients α. The amounts of oligomers and lactic acid are also influenced by α. The mass does not seem very sensitive to changes in β.
Conclusion
In recent years, mathematical modeling has become an effective tool to simulate drug delivery processes in DES leading to a deeper understanding of the drug release mechanism both in biodegradable polymers and in the arteries.
In this paper, a two dimensional mathematical model of in vivo drug delivery from an eluting stent has been developed. Numerical simulations as well as a sensitivity analysis of the parameters have been done using freeFEM++. The degradation of the PLA into oligomers and lactic acid has been taken into account. The process of penetration of the fluid into a biodegradable polymer as well as the process of drug diffusion into the blood and the vessel wall have been analyzed from a numerical viewpoint. The sensitivity of the model to the perturbations of the effective parameters such as diffusion coefficients, reaction rates and autocatalytic parameters is also analyzed. The interplay between these parameters can be used as an efficient tool in the design of the coating polymer in such a way that a predefined drug delivery profile can be obtained.
The cardiovascular drug delivery process is not well understood because it depends on a huge number of complex biochemical and physical phenomena. However a simplified release model as the one presented in this paper can help to give some insight of the dependence of the release profiles on the parameters involved. The introduction of the mechanical properties of the stent and the vessel wall as the coupling with blood flow in the vessel are important aspects that we plan to consider in the near future.
Annex
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